AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15570576 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine (TOL) 4 mg daily for 8 weeks
Number of subjects: 743
Study 15570576 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine (TOL)
Number of subjects: 743
Study 15570576 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 743
Study 12882824 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (DHA) supplementation
Number of subjects: 100
Study 12882824 — intervention group
Group type: COMPARATOR
Intervention: Placebo oleic acid dietary supplement
Number of subjects: 100
Study 10848656 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy
Number of subjects: 286
Study 10848656 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 286
Study 8855733 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (4 weeks)
Number of subjects: 72
Study 1463867 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval cancers
Number of subjects: 333
Study 1463867 — intervention group
Group type: COMPARATOR
Intervention: Control cancers
Number of subjects: 333
Study 3155806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (125 mg, 0.5 mL injection)
Number of subjects: 84
Study 3155806 — intervention group
Group type: COMPARATOR
Intervention: Spectinomycin (2 g injection)
Number of subjects: 84
Study 31628248 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive smartphone application promoting condom use over 180 days
Number of subjects: 433
Study 31628248 — intervention group
Group type: COMPARATOR
Intervention: Dummy application (control group)
Number of subjects: 433
Study 31628248 — intervention group
Group type: COMPARATOR
Intervention: Both groups received standard of care at the Youth Health Clinics (YHC)
Number of subjects: 433
Study 29248640 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg for 6 months (n = 51)
Number of subjects: 194
Study 29248640 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months (n = 54)
Number of subjects: 194
Study 30517723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of 500 mL beer
Number of subjects: 34
Study 30517723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of 500 mL soda
Number of subjects: 34
Study 30517723 — intervention group
Group type: COMPARATOR
Intervention: Ingestion of 500 mL beer and soda
Number of subjects: 34
Study 27005463 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg anamorelin
Number of subjects: 181
Study 27005463 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg anamorelin
Number of subjects: 181
Study 27005463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 24886581 — intervention group
Group type: EXPERIMENTAL
Intervention: Early specific cognitive-behavioural psychotherapy (CBT) including stress management and problem solving strategies, with elements of mindfulness-based therapy (MBT) for 14 weeks.
Number of subjects: 0
Study 24886581 — intervention group
Group type: COMPARATOR
Intervention: Unstructured group meetings for 14 weeks.
Number of subjects: 0
Study 22696845 — intervention group
Group type: EXPERIMENTAL
Intervention: 0, 5-min instillation (Method A) of combined 0.75% tropicamide and 2.5% phenylephrine
Number of subjects: 42
Study 22696845 — intervention group
Group type: EXPERIMENTAL
Intervention: 0, 30-min instillation (Method B) of combined 0.75% tropicamide and 2.5% phenylephrine
Number of subjects: 42
Study 22696845 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 42
Study 21035693 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote superficial femoral artery endarterectomy (RSFAE)
Number of subjects: 116
Study 21035693 — intervention group
Group type: COMPARATOR
Intervention: Supragenicular bypass surgery
Number of subjects: 116
Study 18532970 — intervention group
Group type: EXPERIMENTAL
Intervention: Early catheter removal (immediate removal after surgery)
Number of subjects: 90
Study 18532970 — intervention group
Group type: COMPARATOR
Intervention: Control group (catheter removed at least 24 hours after surgery)
Number of subjects: 90
Study 18532970 — intervention group
Group type: EXPERIMENTAL
Intervention: Early catheter removal
Number of subjects: 90
Study 16053475 — intervention group
Group type: EXPERIMENTAL
Intervention: subcutaneous interferon (IFN) beta‐1a, 22 or 44 mug three times weekly
Number of subjects: 560
Study 16053475 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 560
Study 11834004 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics (fusemide and amiloride)
Number of subjects: 79
Study 11834004 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 79
Study 11834004 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 79
Study 11834004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 12198785 — intervention group
Group type: EXPERIMENTAL
Intervention: Image generation task
Number of subjects: 0
Study 12198785 — intervention group
Group type: EXPERIMENTAL
Intervention: Image maintenance task
Number of subjects: 0
Study 12198785 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning task
Number of subjects: 0
Study 12198785 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotation task
Number of subjects: 0
Study 7487445 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking cadence at 120 steps/min
Number of subjects: 8
Study 7487445 — intervention group
Group type: COMPARATOR
Intervention: Walking cadence at 70 steps/min
Number of subjects: 8
Study 1819543 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride (0.1 mg, 1/2 tablet every 8 hours for 3 months)
Number of subjects: 23
Study 6128451 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased oral potassium 64 mmol a day
Number of subjects: 20
Study 6128451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30798684 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 0
Study 30798684 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 0
Study 29058620 — intervention group
Group type: EXPERIMENTAL
Intervention: POWERS forID intervention (access to the POWERS forID website and health coach calls)
Number of subjects: 70
Study 29058620 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical weight-loss care (control group)
Number of subjects: 70
Study 25207682 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lipid emulsion (20% Intralipid®)
Number of subjects: 8
Study 25207682 — intervention group
Group type: COMPARATOR
Intervention: Ringer's acetate solution
Number of subjects: 8
Study 23475800 — intervention group
Group type: COMPARATOR
Intervention: Conventional 5-mm electrocautery hook (hook group)
Number of subjects: 46
Study 23475800 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-lumen electrocautery tube (DLET group)
Number of subjects: 46
Study 22526529 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DXM) 400 mg/70 kg
Number of subjects: 12
Study 22526529 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 and 0.5 mg/70 kg)
Number of subjects: 12
Study 22526529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19106243 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation (20 g protein/session) before and after exercise
Number of subjects: 26
Study 19106243 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no protein supplementation)
Number of subjects: 26
Study 17888735 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan plus bevacizumab
Number of subjects: 56677
Study 17888735 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan plus oxaliplatin
Number of subjects: 56677
Study 17888735 — intervention group
Group type: EXPERIMENTAL
Intervention: oxaliplatin plus bevacizumab
Number of subjects: 56677
Study 17888735 — intervention group
Group type: EXPERIMENTAL
Intervention: bevacizumab alone
Number of subjects: 56677
Study 17888735 — intervention group
Group type: EXPERIMENTAL
Intervention: oxaliplatin alone
Number of subjects: 56677
Study 17888735 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan plus cetuximab
Number of subjects: 56677
Study 17888735 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan alone
Number of subjects: 56677
Study 15250565 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% nitroglycerine (GTN)
Number of subjects: 64
Study 15250565 — intervention group
Group type: COMPARATOR
Intervention: 5% xylocaine
Number of subjects: 64
Study 15250565 — intervention group
Group type: COMPARATOR
Intervention: Proctosedyl
Number of subjects: 64
Study 15250565 — intervention group
Group type: COMPARATOR
Intervention: Petroleum jelly (Vaseline)
Number of subjects: 64
Study 12495901 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuG-CSF 10 mg/kg
Number of subjects: 221
Study 12495901 — intervention group
Group type: COMPARATOR
Intervention: Control (no rHuG-CSF)
Number of subjects: 221
Study 9667102 — intervention group
Group type: EXPERIMENTAL
Intervention: KH 1060 ointment
Number of subjects: 10
Study 9667102 — intervention group
Group type: COMPARATOR
Intervention: Vehicle only
Number of subjects: 10
Study 9475569 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg)
Number of subjects: 24
Study 9475569 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine (10 mg)
Number of subjects: 24
Study 9475569 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 24
Study 9475569 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine
Number of subjects: 24
Study 1847023 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) at 3 ng.kg‐1.min‐1
Number of subjects: 10
Study 1847023 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) at 6 ng.kg‐1.min‐1
Number of subjects: 10
Study 1847023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6341063 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 50
Study 6341063 — intervention group
Group type: COMPARATOR
Intervention: Urografin (diatrizoate) 60%
Number of subjects: 50
Study 6341063 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol and Urografin
Number of subjects: 50
Study 31790750 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led facilitated advance care planning (ACP) intervention
Number of subjects: 149
Study 31376781 — intervention group
Group type: EXPERIMENTAL
Intervention: Question Formulation Technique (QFT) intervention
Number of subjects: 3173
Study 30188451 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermomechanical stimulation (Buzzy)
Number of subjects: 105
Study 30188451 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 105
Study 27126336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ectoine mouth and throat spray
Number of subjects: 95
Study 27126336 — intervention group
Group type: COMPARATOR
Intervention: Saline lozenges
Number of subjects: 95
Study 27126336 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 95
Study 24572590 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise
Number of subjects: 39
Study 24572590 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute anaerobic exercise
Number of subjects: 39
Study 24572590 — intervention group
Group type: COMPARATOR
Intervention: Athletes group
Number of subjects: 39
Study 24572590 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 22525773 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 63
Study 22525773 — intervention group
Group type: COMPARATOR
Intervention: Life as usual
Number of subjects: 63
Study 22525773 — intervention group
Group type: COMPARATOR
Intervention: Occupational therapy
Number of subjects: 63
Study 20456625 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional sex therapy and/or gingko biloba
Number of subjects: 99
Study 20456625 — intervention group
Group type: COMPARATOR
Intervention: Sexually healthy women (control group)
Number of subjects: 99
Study 17343668 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol fixed combination (DTFC)
Number of subjects: 32
Study 17343668 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost/timolol fixed combination (LTFC)
Number of subjects: 32
Study 17343668 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 32
Study 15760426 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifungal therapy for 2 weeks and 3 months
Number of subjects: 103
Study 15760426 — intervention group
Group type: COMPARATOR
Intervention: Anti-retroviral agents
Number of subjects: 103
Study 12409657 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral neck exploration
Number of subjects: 91
Study 12409657 — intervention group
Group type: COMPARATOR
Intervention: Bilateral neck exploration
Number of subjects: 91
Study 9045329 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m2 and paclitaxel 135 mg/m2
Number of subjects: 386
Study 9045329 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 75 mg/m2 and cyclophosphamide 750 mg/m2
Number of subjects: 386
Study 8345115 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom instruction in body mechanics (2 hours)
Number of subjects: 0
Study 8345115 — intervention group
Group type: COMPARATOR
Intervention: Independent study module
Number of subjects: 0
Study 3490659 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency TENS for 15-20 minutes
Number of subjects: 15
Study 3490659 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with dilute local anesthetics
Number of subjects: 15
Study 3490659 — intervention group
Group type: COMPARATOR
Intervention: Placebo-TENS
Number of subjects: 15
Study 31617769 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol administration by parents after GP consultation
Number of subjects: 548
Study 31617769 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol administration in children aged three to six months
Number of subjects: 548
Study 31617769 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol administration in children aged five to twelve years
Number of subjects: 548
Study 31617769 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of paracetamol administration for common infections
Number of subjects: 548
Study 29402561 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of the implant
Number of subjects: 158
Study 29402561 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading of the implant
Number of subjects: 158
Study 26659706 — intervention group
Group type: COMPARATOR
Intervention: PEGIFN/RBV for 24 or 48 weeks depending on rapid virologic response (RVR)
Number of subjects: 19
Study 26659706 — intervention group
Group type: EXPERIMENTAL
Intervention: BOC add-on therapy at week 12 for patients without cEVR
Number of subjects: 19
Study 24885958 — intervention group
Group type: EXPERIMENTAL
Intervention: Job rotation intervention group
Number of subjects: 957
Study 24885958 — intervention group
Group type: COMPARATOR
Intervention: Control group (no job rotation)
Number of subjects: 957
Study 22744547 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace treatment for 18 hours/day
Number of subjects: 136
Study 22744547 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace treatment for 21 hours/day
Number of subjects: 136
Study 22744547 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace treatment for 23 hours/day
Number of subjects: 136
Study 22744547 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercises
Number of subjects: 136
Study 22744547 — intervention group
Group type: COMPARATOR
Intervention: Observed (Control)
Number of subjects: 136
Study 20334677 — intervention group
Group type: EXPERIMENTAL
Intervention: Interceptor((R)) LLINs
Number of subjects: 398
Study 20334677 — intervention group
Group type: COMPARATOR
Intervention: Conventionally treated nets (CTNs)
Number of subjects: 398
Study 19031770 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke rehabilitation unit
Number of subjects: 150
Study 19031770 — intervention group
Group type: COMPARATOR
Intervention: Ordinary group
Number of subjects: 150
Study 15925295 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 group (n = 9)
Number of subjects: 21
Study 15925295 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 21
Study 12889696 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gel
Number of subjects: 50
Study 12889696 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 50
Study 12889696 — intervention group
Group type: COMPARATOR
Intervention: No treatment (no-gel control)
Number of subjects: 50
Study 12889696 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel
Number of subjects: 50
Study 10550566 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide orally at 50 mg daily and cyclophosphamide orally at 50 mg daily (first cohort)
Number of subjects: 57
Study 10550566 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide orally at 50 mg twice daily and cyclophosphamide orally at 50 mg twice daily (second cohort)
Number of subjects: 57
Study 10550566 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 57
Study 8889904 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin 500 mg orally once daily
Number of subjects: 39
Study 8889904 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin base 250 mg orally four times daily
Number of subjects: 39
Study 1478125 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (4-week treatment)
Number of subjects: 30
Study 1478125 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (3-day treatment)
Number of subjects: 30
Study 6362830 — intervention group
Group type: EXPERIMENTAL
Intervention: BHD plus levamisole
Number of subjects: 280
Study 6362830 — intervention group
Group type: EXPERIMENTAL
Intervention: BHD
Number of subjects: 280
Study 6362830 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose DTIC plus actinomycin D
Number of subjects: 280
Study 6362830 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose DTIC plus actinomycin D (with prior disease-free interval > 6 months)
Number of subjects: 280
Study 6362830 — intervention group
Group type: COMPARATOR
Intervention: Immunotherapy limb (BHD plus levamisole)
Number of subjects: 280
Study 31687935 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit Learning Approach (ILA)
Number of subjects: 0
Study 31687935 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 0
Study 29469022 — intervention group
Group type: EXPERIMENTAL
Intervention: FTO risk allele (AA) in obese black women
Number of subjects: 774
Study 29469022 — intervention group
Group type: EXPERIMENTAL
Intervention: GNB3 non-risk CC homozygotes
Number of subjects: 774
Study 29469022 — intervention group
Group type: EXPERIMENTAL
Intervention: GNB3 C carriers (white women)
Number of subjects: 774
Study 29469022 — intervention group
Group type: EXPERIMENTAL
Intervention: GNB3 homozygote (TT) overweight women
Number of subjects: 774
Study 29469022 — intervention group
Group type: EXPERIMENTAL
Intervention: FTO gene (obese carriers of the risk allele)
Number of subjects: 774
Study 29469022 — intervention group
Group type: EXPERIMENTAL
Intervention: GNB3 heterozygotes (CT)
Number of subjects: 774
Study 25791446 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation (PSI)
Number of subjects: 60
Study 25791446 — intervention group
Group type: COMPARATOR
Intervention: Conventional instrumentation
Number of subjects: 60
Study 24722262 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer‐assisted cognitive training (60 hours over 10 weeks)
Number of subjects: 34
Study 24722262 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 34
Study 21968714 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Control Analgesia (PCA)
Number of subjects: 47
Study 21968714 — intervention group
Group type: COMPARATOR
Intervention: Morphine bolus
Number of subjects: 47
Study 20016381 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 689
Study 17492590 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg/day)
Number of subjects: 96
Study 17492590 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 96
Study 16198334 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy (local and rectal insufflation of the gas)
Number of subjects: 101
Study 16198334 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic therapy (topical and systemic)
Number of subjects: 101
Study 12195347 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART plus low-dose prolonged intermittent interleukin (IL)-2 (n=12)
Number of subjects: 22
Study 12195347 — intervention group
Group type: COMPARATOR
Intervention: HAART alone (n=10)
Number of subjects: 22
Study 10363339 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical model examining treatment efficacy in randomized phase III trials with varying alpha levels and sample sizes.
Number of subjects: 0
Study 10363339 — intervention group
Group type: EXPERIMENTAL
Intervention: Judicious choice of type I error rate and trial size.
Number of subjects: 0
Study 10363339 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall context of research setting and long-term goals in trial design.
Number of subjects: 0
Study 7877932 — intervention group
Group type: EXPERIMENTAL
Intervention: New intestinal recording devices for assessing motility
Number of subjects: 0
Study 2120310 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 443
Study 2120310 — intervention group
Group type: COMPARATOR
Intervention: diatrizoate
Number of subjects: 443
Study 131139 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoxamine or cromolyn sodium inhalation
Number of subjects: 22
Study 131139 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 22
Study 31671060 — intervention group
Group type: EXPERIMENTAL
Intervention: SVG-DES (Drug-Eluting Stent)
Number of subjects: 182
Study 31671060 — intervention group
Group type: COMPARATOR
Intervention: SVG-MT (Medical Treatment)
Number of subjects: 182
Study 28671091 — intervention group
Group type: EXPERIMENTAL
Intervention: dezocine
Number of subjects: 1000
Study 28671091 — intervention group
Group type: COMPARATOR
Intervention: fentanyl
Number of subjects: 1000